J9313 HCPCS Level II code: Injection, moxetumomab pasudotox-tdfk, 0.01 mg
J9313 is the HCPCS code for “Injection, moxetumomab pasudotox-tdfk, 0.01 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9313Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Short description: Inj., lumoxiti, 0.01 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9313 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Oct 1, 2019
Where J9313 sits
- 1J codesDrugs administered other than orally
- 2Active code J9313Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9313 mean?
J9313 is the HCPCS code for “Injection, moxetumomab pasudotox-tdfk, 0.01 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9313?
CMS lists J9313’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9313
All J codesJ9307Injection, pralatrexate, 1 mgJ9308Injection, ramucirumab, 5 mgJ9309Injection, polatuzumab vedotin-piiq, 1 mgJ9310Injection, rituximab, 100 mgJ9311Injection, rituximab 10 mg and hyaluronidaseJ9312Injection, rituximab, 10 mgJ9314Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mgJ9315Injection, romidepsin, 1 mgJ9316Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mgJ9317Injection, sacituzumab govitecan-hziy, 2.5 mgJ9318Injection, romidepsin, non-lyophilized, 0.1 mgJ9319Injection, romidepsin, lyophilized, 0.1 mg